PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
PMCID: PMC2943867
NIHMSID: NIHMS227899

Macrophage Reverse Cholesterol Transport in Mice Expressing ApoA-I Milano

Abstract

Objective

To compare the abilities of human wild type apoA-I (WT apoA-I) and human apoA-IMilano (apoA-IM) to promote macrophage reverse cholesterol transport (RCT) in apoA-I–null mice infected with adeno-associated virus (AAV) expressing either WT apoA-I or apoA-IM.

Methods and Results

WT apoA-I– or apoA-IM–expressing mice were intraperitoneally injected with [H3]cholesterol-labeled J774 mouse macrophages. After 48 hours, no significant difference was detected in the amount of cholesterol removed from the macrophages and deposited in the feces via the RCT pathway between the WT apoA-I and apoA-IM groups. Analysis of the individual components of the RCT pathway demonstrated that the apoA-IM-expressing mice promoted ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux as efficiently as WT apoA-I but that apoA-IM had a reduced ability to promote cholesterol esterification via lecithin cholesterol-acyltransferase (LCAT). This resulted in reduced cholesteryl ester (CE) and increased free cholesterol (FC) levels in the plasma of mice expressing apoA-IM compared to WT apoA-I. These differences did not affect the rate of delivery of labeled cholesterol to the liver via SR-BI–mediated selective uptake or its subsequent excretion in the feces.

Conclusion

Within the limits of the in vivo assay, WT apoA-I and apoA-IM are equally efficient at promoting macrophage RCT, suggesting that if apoA-IM is more atheroprotective than WT apoA-I it is not due to an enhancement of macrophage RCT.

Keywords: apoA-I Milano, reverse cholesterol transport, high density lipoprotein, macrophage, apolipoprotein

Apolipoprotein A-I (apoA-I) is the major protein component of HDL.1,2 Plasma apoA-I and HDL cholesterol levels are inversely associated with the risk of cardiovascular disease.3 The antiatherogenic properties of apoA-I are thought to arise, at least in part, from its central role in reverse cholesterol transport (RCT), the pathway by which excess cholesterol is effluxed from peripheral tissues and transported to the liver, where it is subsequently excreted from the body.35

The first natural mutant of apoA-I identified was the apoA-IMilano (apo A-IM) mutation (R173C).6 The apoA-IM mutation is located in the N-terminal helix bundle domain of the protein.7,8 Naturally occurring variants of apoA-I between residues 121 and 186 are often associated with low apoA-I levels.9 Individuals heterozygous for the apoA-IM mutation have very low plasma apoA-I and HDL cholesterol levels as well as moderately elevated triglycerides.10 Despite a lipid profile that is usually associated with a high risk of premature cardiovascular disease, apoA-IM carriers display no increase in cardiovascular disease or events.1012 This has led to speculation that apoA-IM is a gain-of-function mutation that has enhanced cardio-protective effects,1319 whereas others believe that wild-type (WT) apoA-I and apoA-IM are functionally equivalent.20,21 A clinical trial of repeated intravenous infusions of apoA-IM–phospholipid complexes demonstrated regression of existing atheromas after 5 weekly treatments,22,23 whereas other clinical trials focused on the ability of WT apoA-I/phosphatidylcholine disks to increase endothelial function.24,25

To date it has not been determined how the R173C substitution affects RCT in vivo. To investigate this question we performed the first head-to-head comparison of in vivo macrophage-RCT between WT apoA-I and apoA-IMilano using an assay developed in our laboratory.

Methods

Preparation of ApoA-I Mutants

The cDNAs of interest were expressed in Escherichia coli and the resulting proteins purified to greater than 95% purity by gel filtration chromatography.7 All proteins were stored at −80°C in lyophilized form and before use were dissolved in the appropriate buffer containing 6 mol/L Gdn HCl and dialyzed extensively before use.

Preparation of ApoA-I Adeno-Associated Virus

Wt apoA-I cDNA was mutated using the Quikchange Site-Directed Mutagenesis Kit from Stratagene. The resulting cDNA were sequenced to confirm the presence of the intended mutation and submitted to the University of Pennsylvania Vector Core for use in creating the liver-specific apoA-I adeno-associated virus (AAV) serotype 8.26

Macrophage RCT Studies

Experiments were performed in male apoA-I–null mice obtained from Jackson Labs and fed a chow diet. For each experiment, 18 mice (n=6/group) received i.p. injection of AAV8 (1×1012 GC) containing either WT apoA-I, apoA-IM, or LacZ cDNA. On day 42 after vector injection, each animal received intraperitoneal injections of [3H]cholesterol-labeled J774 cells. Blood was collected at 2, 6, 24 and 48 hours. Feces was collected from 0 to 48 hours, and after exsanguinations at 48 hours bile and liver samples were collected as previously described.27

Endogenous LCAT Assays

The endogenous LCAT cholesterol esterification rate (CER) in whole plasma was measured using a modified Stokke and Norum procedure.2830 Seventy-five microliters of fresh non-radioactive plasma were incubated with a BSA solution containing 3×106 dpm of [3H]cholesterol on ice overnight to allow the [3H]cholesterol tracer to equilibrate evenly across the entire spectrum of lipoproteins. The plasma was then incubated at 37°C for 30 minutes as duplicates while a third aliquot was maintained at 4°C as a control. Lipids were extracted by TLC. Endogenous LCAT activity was expressed as nanomoles of CE formed per mL of plasma during the 30 minutes incubation.

Cholesterol Efflux

After [3H]cholesterol labeling the cells (J774 or mouse peritoneal macrophage [MPM]), media containing the appropriate acceptor was added for up to 24 hours. In some experiments the ACAT inhibitor CP113 818 (2 µg/mL) was added to the media. To determine the cholesterol efflux, media were sampled at indicated times, filtered, and counted by liquid scintillation counting to determine the [3H] released. [3H] in the media was compared with total [3H] at time zero to determine the percent release of [3H]cholesterol.3133 ABCA1-mediated efflux was calculated by %efflux+cAMP–%efflux−cAMP.

Cholesterol Influx

Rat Fu5AH hepatoma cells were prepared as described previously34 and incubated with 20% serum containing [3H]cholesterol and [3H]cholesteryl ester from mice expressing either WT apoA-I or apoA-IM. After 8 hours, the cells were washed 3 times with PBS, the cell lipids were extracted with isopropyl alcohol as previously described,35 and the levels of tritium label determined.

Data Analysis

Data are from representative experiments and are expressed as mean±SD. Statistical test for significance was done using an unpaired t test or 1-way Anova followed by a Tukey test for pairwise comparisons.

Additional materials and methods are available in the supplemental materials (available online at http://atvb.ahahournals.org).

Results

In Vivo RCT studies

ApoA-I–null mice (n=6 per group) were IP injected with AAV-expressing WT apoA-I, apoA-IM, or LacZ control at a dose of 1×1012 genome copies (GC). Six weeks after infection, WT apoA-I– and apoA-IM–expressing mice roughly reproduced the relative apoA-I and lipid levels of the human apoA-IM carriers and their controls36; apoA-IM–expressing mice had lower plasma apoA-I and substantially lower HDL-C levels compared with WT apoA-I-expressing mice (Table). Differences between the groups were not attributable to differential gene expression, as hepatic mRNA levels of WT apoA-I and apoA-IM were similar (supplemental Figure I). At week 6 after AAV injection, cholesterol-labeled J774 cells were injected for a macrophage RCT study. The [3H]-cholesterol counts in plasma, expressed as a percentage of total labeled cholesterol injected, at each time point were significantly higher for WT apoA-I compared to apoA-IM or LacZ mice (Figure 1A). Expression of human WT apoA-I significantly increased the transport of macrophage-derived cholesterol into the feces compared to the LacZ control (Figure 1B). However, there was no significant difference in counts in either the liver and bile (supplemental Table I) or the feces (Figure 1B) between WT apoA-I and apoA-IM mice despite the lower plasma levels of apoA-I and HDL cholesterol for apoA-IM–expressing mice. FPLC profiles of pooled plasma samples from the 48-hour time point indicated that the HDL formed by WT apoA-I and apoA-IMilano–expressing mice were similar (Supplemental Figure II).

Figure 1
Reverse cholesterol transport assay. Male apoA-I–null mice (n=6 per group) were injected with AAV (1×1012 GC) expressing either WT apoA-I, apoA-IMilano, or LacZ 6 weeks before the RCT assay. The mice were then IP injected with [3H]cholesterol-labeled, ...
Table
Plasma Lipid and ApoA-I Levels

In a subsequent experiment the dose of WT apoA-I AAV was reduced 5-fold, whereas the apoA-IM dose was held constant in an attempt to equalize the level of HDL-C between WT apoA-I– and apoA-IM–expressing mice. This treatment resulted in substantially reduced apoA-I levels in mice expressing WT apoA-I and similar levels of HDL-C in the WT apoA-I and apoA-IM mice, (Table). Compared with the lacZ control mice, expression of low dose WT apoA-I promoted significantly increased plasma counts and fecal excretion of tracer (Figure 1C and 1D), although to a lesser extent than the higher dose experiment. However, there remained no significant difference between apoA-IMilano–expressing and WT apoA-I– expressing mice in fecal tracer excretion despite the much lower plasma levels of WT apoA-I.

ABCA1-Mediated Cholesterol Efflux

To gain further insight into the effect of apoA-IM compared with WT apoA-I on RCT, we investigated each of the steps of RCT individually; these steps include ABCA1-mediated cholesterol efflux, the conversion of free cholesterol to cholesteryl ester by LCAT, and SR-BI–mediated selective uptake of cholesterol and cholesteryl ester from HDL particles.3

To measure ABCA1-mediated cholesterol efflux, J774 macrophages (the cells used in the macrophage RCT experiments) and MPM were labeled with [3H]-cholesterol. After an equilibration period, 2.5% serum from either WT apoA-I– or apoA-IM–expressing mice (from RCT #1) was added for 4 hours. As previously reported for MPMs32 there were no differences in ABCA1-mediated cholesterol efflux (3.6±0.9% for WT apoA-I and 4.6±1.5% for apoA-IM). This finding was confirmed with J774 macrophages which were used in the macrophage RCT experiments described above (7.9±0.8% for WT apoA-I and 8.5±1.2% for apoA-IM; Figure 2A). This was a somewhat surprising observation given the lower concentration of apoA-IM compared to WT apoA-I in the serum samples (Table). To address this issue, recombinant WT apoA-I and apoA-IM (in the monomeric and homodimeric states) were used at different concentrations (0 to 20 µg/mL) as acceptors for ABCA1-mediated efflux of [3H]-cholesterol from J774 macrophages (Figure 2B). From these experiments, the kinetic constants of the ABCA1 reactions were determined and the Km values for cholesterol efflux to WT apoA-I, monomeric, and dimeric apoA-IMilano were 4.5±0.5, 2.1±0.3, and 4.8±0.9 µg apoA-I/ml, respectively. The VMax values of the reaction for WT apoA-I, monomeric, and dimeric apoA-IMilano were 7.5±0.3, 5.2±0.2, and 5.8±0.4% cholesterol efflux/4 hour, respectively.

Figure 2
ABCA1-mediated efflux from macrophages to serum. J774 macrophages were labeled with [3H] cholesterol as described under Materials and Methods. These labeled cells were then treated with cAMP overnight to upregulate ABCA1. The lipid efflux was then initiated ...

Conversion of Free-Cholesterol to Cholesteryl Ester by LCAT

The second step in the RCT process is the conversion of FC to CE by LCAT in the plasma. The cholesterol esterification rates (CER), as determined in the Materials and Methods, for apoA-IM– and LacZ-expressing mice were 45% and 18%, respectively, of that of the WT apoA-I–expressing mice (Figure 3A). Corresponding to the reduction in the CER, plasma CE levels in apoA-IM– and LacZ-expressing mice were significantly reduced compared to the WT apoA-I–expressing animals (Figure 3B).

Figure 3
LCAT cholesterol esterification rates. A, Cholesterol esterification rate in the plasma of mice expressing WT apoA-I or apoA-IMilano. Whole plasma was radiolabeled with [3H]cholesterol at 4°C overnight and then incubated at 37°C for 30 ...

SR-BI–Mediated Selective Uptake

The third step of the RCT pathway is the SR-BI–mediated selective uptake of cholesterol from HDL in the plasma into the liver. Serum samples from the 48-hour time point of the RCT experiment in Figure 2C, which contain [3H]-cholesterol and [3H]-cholesteryl ester, were diluted in media and applied to Fu5AH rat liver hepatoma cells that express high levels of SR-BI37 and incubated for 8 hours. After the 8-hour incubation, the cells were processed as described in the Materials and Methods to determine the amount of label that was taken up from the media into the cells (Figure 4). Serum from mice expressing either WT apoA-I or apoA-IM was equally effective at promoting SR-BI–mediated selective CE and FC uptake into these liver cells.

Figure 4
SR-BI–mediated influx of cholesterol from mouse plasma to hepatic cells. [3H]cholesterol and [3H]cholesteryl ester–labeled serum from the 48-hour time point of the experiment described in Figure 2C was diluted to 20% with media and incubated ...

Discussion

Carriers of the apoA-IM variant have reduced levels of plasma apoA-I and HDL, but no corresponding increase in cardiovascular disease compared to individuals with the WT apoA-I gene.1012 One theory used to explain this inconsistency is that HDL containing apoA-IM are more efficient at promoting RCT. This study is the first direct comparison of the ability of WT apoA-I and apoA-IM to promote macrophage RCT in vivo.

ApoA-I–null mice were injected with AAV expressing either WT apoA-I, apoA-IM, or the LacZ control. The mice were then used in macrophage RCT experiments. In the first macrophage RCT experiment, the relative amounts of apoA-I and HDL-C levels in WT apoA-I– and apoA-IM–expressing mice closely approximated the levels seen in humans,36 with lower apoA-I and HDL-C levels in mice expressing apoA-IM (Table). When the mice were assayed for the ability to promote macrophage RCT, there was no significant difference between the WT apoA-I and apoA-IM groups in fecal excretion of tracer (Figure 1A and 1B) despite the lower HDL-C levels in the latter group. In the second experiment, the amount of WT apoA-I AAV used was reduced so that the resulting HDL-C levels in the WT apoA-I and apoA-IM mice were equal (Table). Surprisingly, despite much lower plasma apoA-I levels in the mice expressing WT apoA-I, there was still no significant difference in fecal tracer excretion between mice expressing WT apoA-I and mice expressing apoA-IM. This result suggests that apoA-IM is not more effective than WT apoA-I at promoting macrophage RCT as assessed by this model. To gain greater insight, we dissected the following 3 steps of the RCT pathway, ABCA1-mediated cholesterol efflux, LCAT-mediated conversion of FC to CE, and SR-BI–mediated selective uptake of cholesterol.

Serum from mice expressing apoA-I at levels similar to those listed in Table, RCT 1, was used to measure ABCA1-mediated cholesterol efflux (the transporter responsible for a majority of the cholesterol efflux37) from J774 macrophages, the cell type used in the macrophage RCT experiments. Both WT apoA-I and apoA-IM serum promoted efflux to similar extents (Figure 2A) despite lower levels of apoA-I in the apoA-IM mice compared to the WT apoA-I mice.32 To address this issue, we measured the effects of apoA-I concentration on ABCA1-mediated cholesterol efflux from J774 cells (Figure 2B) and determined that Km of the reactions were in the range of 2 to 5 µg/mL of apoA-I for WT and apoA-IM. In the serum of the WT apoA-I and apoA-IM mice, if one conservatively estimates that 5% of the circulating apoA-I is in the lipid-free or lipid-poor state,38,39 the concentrations would be 77 and 61 µg/mL, respectively. These levels are well above the Km of the ABCA1 reaction so that the reaction would be operating near maximal levels. Even if the fact that the levels of apoA-I present in interstitial fluid would be lower than in the serum40 is taken into account, the concentration of apoA-I would still be well above the Km of the reaction. The level of lipid-free or lipid-poor apoA-I in the second RCT experiment would also have been well above the saturation point of the ABCA1-mediated reaction. It should also be noted that measurements of pre-β HDL in human apoA-IM carriers determined that 15% of the apoA-I was in the lipid-free or lipid-poor state,36 consistent with saturating conditions for the apoA-I/ABCA1 reaction.41,42 It is also worth noting that although ABCA1 is responsible for transferring cholesterol to lipid-poor apoA-I, ABCG1 can transfer cholesterol to lipidated apoA-I and that the Km of the ABCG1 reaction is approximately 50 µg/mL HDL protein.43 The concentration of WT apoA-I and apoA-IM in the mice is above the Km of the ABCG1 reaction.

The second step of the RCT process, the conversion of FC to CE by LCAT in the plasma, was measured in plasma using well established methods.29 The results demonstrated that apoA-IM was unable to activate mouse LCAT to the same extent as WT apoA-I (Figure 3). This result with plasma HDL confirmed earlier work,44 showing that recombinant HDL made with dimeric apoA-IM was 70% less efficient as a substrate for human LCAT than recombinant HDL prepared with WT apoA-I. Structural analysis of the apoA-IM mutation45 determined that the loss of the arginine and the gain of the cysteine residue at position 173 destabilized the N-terminal helix bundle of the apoA-I molecule, a region that has been determined to be of particular importance for LCAT activation.9

The third step of RCT is the selective uptake of plasma HDL cholesterol by SR-BI into the liver. Serum from WT apoA-I and apoA-IM mice was equally effective at promoting SR-BI selective uptake (Figure 4). The apoA-IM mouse serum had a higher FC/CE ratio compared to the WT apoA-I serum (Figure 3B) because of the reduced LCAT activation by apoA-IM compared to WT apoA-I. Previous work has shown that SR-BI can mediate the selective uptake of both CE and FC from HDL, with the rate constant for the latter being some 60% higher.46 Thus, the alteration in FC/CE ratio between the WT and apoA-IM HDL is unlikely to be harmful to net hepatic selective uptake of HDL cholesterol. Furthermore, the Km for high affinity selective uptake from HDL by SR-BI is approximately 1 µg apoA-I/mL.47 Thus, the concentrations of apoA-I in the WT apoA-I and apoA-IM mouse serum samples are far above the Km that the reaction is saturated and any HDL compositional or quantity differences do not affect SR-BI–mediated selective uptake.

Despite lower apoA-I and HDL-C levels and a reduced ability to activated LCAT, expression of apoA-IM is as efficient at promoting RCT as expression of WT apoA-I as assessed by this mouse tracer assay. However, even when WT apoA-I is expressed at a lower level (plasma levels one-fourth of those in apoA-IM mice) to generate similar levels of HDL-C in both groups of mice, expression of apoA-IM is not more effective in promoting RCT. Thus, if apoA-IMilano does have an enhanced cardioprotective ability, it is likely attributable to other properties of this mutant protein; for example increased antioxidant activity15 arising from the presence of a cysteine residue in the primary structure of apoA-I or the ability of apoA-IMilano to modulate vascular function.12,25

Supplementary Material

ATVB

Acknowledgments

Sources of Funding

This work was supported by AHA grant 0625372U and NIH grants HL22633, HL063768, and HL59407.

Footnotes

Reprints: Information about reprints can be found online at http://www.lww.com/reprints

Disclosures

None.

References

1. Davidson WS, Thompson TB. The structure of apolipoprotein A-I in high density lipoproteins. J Biol Chem. 2007;282:22249–22253. [PubMed]
2. Thomas MJ, Bhat S, Sorci-Thomas MG. Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res. 2008;49:1875–1883. [PMC free article] [PubMed]
3. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221–1232. [PubMed]
4. Yancey PG, Bortnick AE, Kellner-Weibel G, De La Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:712–719. [PubMed]
5. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26:12–19. [PubMed]
6. Weisgraber KH, Rall SC, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. Apolipoprotein A-Imilano - detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem. 1983;258:2508–2513. [PubMed]
7. Saito H, Dhanasekaran P, Nguyen D, Holvoet P, Lund-Katz S, Phillips MC. Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J Biol Chem. 2003;278:23227–23232. [PubMed]
8. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HMK. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA. 2006;103:2126–2131. [PubMed]
9. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med. 2002;12:121–128. [PubMed]
10. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E. Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant - The Limone sul Garda study. Circulation. 2001;103:1949–1954. [PubMed]
11. Gualandri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB, Cerrone A, A M. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083–1097. [PubMed]
12. Gomaraschi M, Baldassarre D, Amato M, Eligini S, Conca P, Sirtori CR, Franceschini G, Calabresi L. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I-Milano mutant. Circulation. 2007;116:2165–2172. [PubMed]
13. Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR, Canavesi M, Bernini F. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999;19:1257–1262. [PubMed]
14. Calabresi L, Canavesi M, Bernini F, Franceschini G. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry. 1999;38:16307–16314. [PubMed]
15. Bielicki JK, Oda MN. Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41:2089–2096. [PubMed]
16. Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol. 2006;48:1459–1468. [PMC free article] [PubMed]
17. Parolini C, Marchesi M, Lorenzon P, Castano M, Balconi E, Miragoli L, Chaabane L, Morisetti A, Lorusso V, Martin BJ, Bisgaler CL, Krause B, Newton RS, Sirtori CR, Chiesa G. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I-Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques - In vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol. 2008;51:1098–1103. [PubMed]
18. Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badirnon L, Fuster V, Badimon JJ. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I-Milano (ETC-216) administration - Magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol. 2008;51:1104–1109. [PubMed]
19. Marchesi M, Booth EA, Rossoni G, Garcia RA, Hill KR, Sirtori CR, Bisgaier CL, Lucchesi BR. Apolipoprotein A-I-Milano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis. 2008;197:572–578. [PubMed]
20. Parolini C, Chiesa G, Gong E, Caligari S, Cortese MM, Koga T, Forte TM, Rubin EM. Apolipoprotein A-I and the molecular variant apoA-IMilano: Evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis. 2005;183:222–229. [PubMed]
21. Lebherz C, Sanmiguel J, Wilson J, Rader D. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007;6:15. [PMC free article] [PubMed]
22. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA. 2003;290:2292–2300. [PubMed]
23. Nicholls SJ, Tuzcu EM, Crowe T, Sipahi I, Schoenhagen P, Kapadia S, Hazen SL, Wun CC, Norton M, Ntanios F, Nissen SE. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006;47:1967–1975. [PubMed]
24. Nieuwdorp M, Vergeer M, Bisoendial RJ, Roodt JO, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, Kastelein JJP, Stroes ESG. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008;51:1081–1084. [PMC free article] [PubMed]
25. Bisoendial RJ, Hovingh GK, Levels JHM, Lerch PG, Andresen I, Hayden MR, Kastelein JJP, Stroes ESG. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–2948. [PubMed]
26. Tanigawa H, Billheimer JT, Fuki I, Thoyama JC, Rothblat G, Rader DJ. AAV8-mediated overexpression of lecithin-cholesterol acyltransferase fails to promote macrophage reverse cholesterol transport in vivo. Circulation. 2007;116:197–197.
27. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216–2224. [PMC free article] [PubMed]
28. Stokke KT, Norum KR. Determination of lecithin - cholesterol acyltransfer in human blood plasma. Scand J Clin Lab Invest. 1971;27:21, 27. [PubMed]
29. Zhao Y, Thorngate FE, Weisgraber KH, Williams DL, Parks JS. Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry. 2005;44:1013–1025. [PubMed]
30. Alexander E, Bhat S, Thomas M, Weinberg R, Cook V, Bharadwaj M, Sorci-Thomas M. Apolipoprotein A-I helix 6 negatively charged residues attenuate lecithin-cholesterol acyltransferase (LCAT) reactivity. Biochemistry. 2005;44:5409–5419. [PubMed]
31. De la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb. 1994;14:1056–1065. [PubMed]
32. Weibel GL, Alexander ET, Joshi MR, Rader DJ, Lund-Katz S, Phillips MC, Rothblat GH. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol. 2007;27:2022–2029. [PubMed]
33. Williams KJ, Tall AR, Bisgaier C, Brocia R. Phospholipid liposomes acquire apolipoprotein-E in atherogenic plasma and block cholesterol loading of cultured macrophages. J Clin Invest. 1987;79:1466–1472. [PMC free article] [PubMed]
34. Zimetti F, Weibel GK, Duong M, Rothblat GH. Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res. 2006;47:605–613. [PubMed]
35. Yancey PG, De la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000;275:36596–36604. [PubMed]
36. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I-Milano dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007;282:5125–5132. [PubMed]
37. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res. 2007;48:2453–2462. [PubMed]
38. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421–428. [PubMed]
39. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211–228. [PubMed]
40. Nanjee MN, Cooke CJ, Olszewski WL, Miller NE. Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph. Arterioscler Thromb Vasc Biol. 2000;20:2148–2155. [PubMed]
41. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, Phillips MC. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem. 2007;282:25123–25130. [PubMed]
42. Vedhachalam C, Ghering AB, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC. ABCA1-induced cell surface binding sites for ApoA-I. Arterioscler Thromb Vasc Biol. 2007;27:1603–1609. [PubMed]
43. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, Rothblat GH. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res. 2008;50:275–284. [PMC free article] [PubMed]
44. Calabresi L, Franceschini G, Burkybile A, Jonas A. Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. Biochem Biophys Res Commun. 1997;232:345–349. [PubMed]
45. Alexander ET, Tanaka M, Kono M, Saito H, Rader DJ, Phillips MC. Structural and functional consequences of the milano mutation (R173C) in human apolipoprotein A-I. J. Lipid Res. 2009;50:1409–1419. [PMC free article] [PubMed]
46. Thuahnai ST, Lund-Katz S, Williams DL, Phillips MC. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. influence of the nature of the donor particle interaction with the receptor. J Biol Chem. 2001;276:43801–43808. [PubMed]
47. Thuahnai ST, Lund-Katz S, Dhanasekaran P, de la Llera-Moya M, Connelly MA, Williams DL, Rothblat GH, Phillips MC. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol: Influence of high density lipoprotein size and structure. J Biol Chem. 2004;279:12448–12455. [PubMed]